GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » ROC %

Immunomedics (Immunomedics) ROC % : -445.14% (As of Jun. 2020)


View and export this data going back to 1990. Start your Free Trial

What is Immunomedics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Immunomedics's annualized return on capital (ROC %) for the quarter that ended in Jun. 2020 was -445.14%.

As of today (2024-05-06), Immunomedics's WACC % is 7.65%. Immunomedics's ROC % is -720.17% (calculated using TTM income statement data). Immunomedics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Immunomedics ROC % Historical Data

The historical data trend for Immunomedics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunomedics ROC % Chart

Immunomedics Annual Data
Trend Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Dec19
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,886.48 -1,598.94 -157.71 -227.59 -905.03

Immunomedics Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -674.35 -888.58 -900.96 -779.39 -445.14

Immunomedics ROC % Calculation

Immunomedics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2019 is calculated as:

ROC % (A: Dec. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2018 ) + Invested Capital (A: Dec. 2019 ))/ count )
=-324.838 * ( 1 - 0% )/( (27.869 + 43.916)/ 2 )
=-324.838/35.8925
=-905.03 %

where

Immunomedics's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2020 is calculated as:

ROC % (Q: Jun. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2020 ) + Invested Capital (Q: Jun. 2020 ))/ count )
=-212.048 * ( 1 - 0% )/( (40.22 + 55.053)/ 2 )
=-212.048/47.6365
=-445.14 %

where

Invested Capital(Q: Jun. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1077.13 - 59.862 - ( 975.518 - max(0, 81.261 - 1043.476+975.518))
=55.053

Note: The Operating Income data used here is four times the quarterly (Jun. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunomedics  (NAS:IMMU) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Immunomedics's WACC % is 7.65%. Immunomedics's ROC % is -720.17% (calculated using TTM income statement data). Immunomedics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Immunomedics ROC % Related Terms

Thank you for viewing the detailed overview of Immunomedics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunomedics (Immunomedics) Business Description

Traded in Other Exchanges
N/A
Address
300 The American Road, Morris Plains, NJ, USA, 07950
Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.
Executives
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt director
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc director, 10 percent owner, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh director, 10 percent owner, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian director, officer: President and CEO 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews officer: Chief Human Resources Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg officer: General Counsel 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik officer: Chief Business Officer & CFO 300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney officer: Chief Commerical Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri officer: Chief Medical Officer

Immunomedics (Immunomedics) Headlines

From GuruFocus

Immunomedics: A Solid Cancer Research Play

By Ishan Majumdar Ishan Majumdar 07-08-2020